A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: A randomized, open-label study

Endocrine Practice

Volumn 17, Issue 1, 2011, Pages 41-50

  Ligthelm, Robert J ^a   Gylvin, Titus ^b,d   DeLuzio, Tony ^b   Raskin, Philip ^c  

^a EHM Clinic   (Netherlands)

^b NOVO NORDISK INC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEPATOBILIARY DISEASE; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79952384658     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP10079.OR     Document Type: Article

References (21)

1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-885. (Pubitemid 36929359)
2. Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM; BIAsp-3021 study group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:724-732. (Pubitemid 47261854)
3. Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract. 2006;72:265-270. (Pubitemid 43729134)
4. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114:527-532. (Pubitemid 44870902)
5. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17:307-313. (Pubitemid 37315939)
6. Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265. (Pubitemid 40170923)
7. Raskin P, Matfin G, Schwartz SL, et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin Plus Oral Agents). Diabetes Obes Metab. 2009;11:27-32.
8. Strojek K, Bebakar WM, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: An open-label, multinational RCT. Curr Med Res Opin. 2009;25:2887-2894.
9. Jang HC, Guler S, Shestakova M; PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract. 2008;62:1013-1018. (Pubitemid 351793600)
10. Gumprecht J, Benroubi M, Borzi V, et al; IMPROVE Study Group Expert Panel. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: A subgroup analysis of the IMPROVE observational study. Int J Clin Pract. 2009;63:966-972.
11. Anderson RT, Skovlund SE, Marrero D, et al. Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther. 2004;26:565-578. (Pubitemid 38586458)
12. Unnikrishnan AG, Tibaldi J, Hadley-Brown M, et al. Practical guidance on intensification of insulin therapy with BIAsp 30: A consensus statement. Int J Clin Pract. 2009;63:1571-1577.
13. Holman RR, Thorne KI, Farmer AJ, et al; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-1730. (Pubitemid 350005153)
14. Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with type 2 diabetes. J Endocrinol Invest. 2009;32:23-27.
15. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: A randomized controlled trial. Diabetes Obes Metab. 2009;11:45-52.
16. Valensi P, Benroubi M, Borzi V, et al; IMPROVE Study Group Expert Panel. The IMPROVE study - A multinational, observational study in type 2 diabetes: Baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62:1809-1819.
17. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet Med. 2004;21:171-175. (Pubitemid 38221817)
18. Ceriello A, Davidson J, Hanefeld M, et al; International Prandial Glucose Regulation Study Group. Postprandial hyperglycaemia and cardiovascular complications of diabetes: An update. Nutr Metab Cardiovasc Dis. 2006;16:453-456.
19. Boehm BO, Vaz JA, Brøndsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004;15:496-502. (Pubitemid 40164478)
20. Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26:531-540. (Pubitemid 38586454)
21. McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: A double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30:1044-1048. (Pubitemid 46684622)